Journals / Endokrinolojide Diyalog Dergisi / 2010 / Cilt: 7 - Sayı: 3

Approach to thyroglobulin-positive, iodine-131 whole body scan-negative differentiated thyroid cancer patients

Diferansiye tiroid karsinomlarmm izleminde iyot-131 sintigrafisi negatif, Tg pozitif hastalara yaklaşım

Pages
117–120
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Here we report the causes of false negative whole body scan or false positive Tg results.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Differentiated thyroid carcinoma is the most common malignant tumor of thyroid.
📊
Key Findings & Data:About 5-20% of patients develop local or regional recurrences after initial surgery.
💡
Conclusion & Impact:Here we report the causes of false negative whole body scan or false positive Tg results.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Differentiated thyroid carcinoma is the most common malignant tumor of thyroid. Although long-term survival is common, patients are at risk of tumor recurrence. About 5-20% of patients develop local or regional recurrences after initial surgery. Because recurrence is a frequent finding during the follow-up of thyroid cancer, many methods have been proposed to identify metastasis after surgery. The different methods available for this follow-up include basal and stimulated thyroglobulin (Tg) measurement and 131I whole body scan (WBS) None of these tools are perfect. WBS and Tg are usually concordant but in some instances may be discordant. False negative WBS or false positive Tg cause to decrease the diagnostic accuracy of metastasis. Here we report the causes of false negative whole body scan or false positive Tg results.

Özet

Diferansiye tiroid kanserleri, tiroidin en sık görülen malign tümörleridir. Uzun dönem sağkalımlarının iyi olmasına karşın, hastalarda tümör nüksü riski vardır. İlk ameliyattan sonra hastaların %5-20’sinde lokal veya bölgesel nüks saptanır. Tiroid kanserlerinin izlem sürecinde nüksler ortaya çıktığı için, metastazların belirlenmesinde çeşitli yöntemler kullanılmaktadır. Bunlar arasında bazal veya uyarılmış tiroglobulin ölçümü ile 131I ile tüm vücut sintigrafisi de bulunmaktadır. Bu yöntemlerin hiçbiri mükemmel değildir. Tüm vücut sintigrafisi ile tiroglobülin ölçümü bazı hastalarda birbiri ile uyumlu olurken, bazılarında uyumsuzluk gösterir. Yalancı negatif tüm vücut sintigrafisi veya yalancı pozitif tiroglobülin sonuçları, metastazların belirlenme duyarlılığının azalmasına neden olur. Bu yazıda yalancı negatif tüm vücut sintigrafisi veya yalancı pozitif tiroglobülin sonuçlarının nedenlerini sunduk.

🔖

Cite This Article

ADALET, I. (2022). Approach to thyroglobulin-positive, iodine-131 whole body scan-negative differentiated thyroid cancer patients. Endokrinolojide Diyalog Dergisi, Cilt: 7 - Sayı: 3, 117–120. https://ajindex.com/articles/500787

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Mazzaferri EL. Overview of management of differentiated thyroid carcinoma in patients with negative whole body radioiodine scans and elevated serum thyroglobulin levels. In Amdur RJ, Mazzaferri EL, eds. Essentials of thyroid cancer management. Springer, 2005: 303-311
  2. Pacini F, Castagna MG, Brilli L, Jost L. Differentiated thyroid cancer: ESMO clinical recommendations for diagnosis, treatment and follow –up. Ann Oncol 2008;19 (Supp 2):99-101
  3. Pacini F, DeGroot LJ. Thyroid neoplasia. In DeGroot LJ, Jameson JL, eds.Endocrinology. Elseiver Saunders, fifth edition, 2006:2147-2180
  4. Durante C, Haddy N, Baudin E, et al. Long term outcome of 444 patients with distant metastasesfrom papillary and follicular thyroid carcinoma:benefits and limits of radioiodine theraphy. J Clin Endocrinol Metab 2006;91:1892-1899
  5. Ashcraft MW, Van Herle AJ. The comparative value of serum thyroglobulin measurements and iodine-131 total body scans in the follow up study of patients with treated differentiated thyroid cancer. Am J Med 1981;71:806-810
  6. Pacini F, Lippi F, Formica N, et al. Therapeutic doses of iodine -131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med 1987;28:1888-1891
  7. Mazzaferri EL. Threating high thyroglobulins with radioiodine. A magic bullet or a shot in the dark? J Clin Endocrinol Metab 1995;80:1485-1487
  8. Waxman A, Ramanna L, Chapman N, et al. The significance of I-131 scan dose in patients with thyroid cancer:determination of ablation. J Nucl Med 1981;22:861-865
  9. Ma C, Kuang A, Xie J, Ma T. Possible explanations for patients with discordant findings of serum thyroglobulin and I131 whole body scanning. J Nucl Med 2005;46:1473-1480
  10. Wong KT, Choi FP, Lee YY, Ahuja AT. Current role of radionuclide imaging in differentiated thyroid cancer. Cancer Imaging 2008;8:159-162
  11. Torrens JI, Burch HB. Serum thyroglobulin measurement: utility in clinical practice. Endocrinol Metab Clin North Am 2001;30:429-467
  12. Pacini F, Agate L, Elisei R, et al. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic 131-I whole body scan:comparison of patients treated with high 131-I activities versus untreated patients. J Clin Endocrinol Metab 2001;86:4092-4097
  13. Baudin E, Cao CD, Cailleux AF, et al. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patie